Celgene International Sárl Release: Randomized Phase III Study Comparing REVLIMID(R) Plus Melphalan and Prednisone (MPR) Compared to Autologous Stem Cell Transplant Presented at American Society of Clinical Oncology

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either lenalidomide (REVLIMID), melphalan and prednisone (MPR) or melphalan plus autologous stem cell transplant (MEL200) following an induction treatment of lenalidomide plus low-dose dexamethasone (Rd) were presented at the American Society of Clinical Oncology annual meeting.